Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases-Reference-Cited by-同舟云学术

Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases

Published:2015-10-21 Issue: Volume: Page:kev374
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Souto Alejandro,Maneiro José Ramón,Gómez-Reino Juan J.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/55/3/523/17389340/kev374.pdf

Reference132 articles.

1. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?

2. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

3. Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

4. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

5. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.;Aletaha;J Rheumatol,2002

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor;Advances in Therapy;2024-08-07

2. Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis?;Reumatología Clínica;2024-08

3. Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs;Drugs;2024-07-01

4. The use of biological and targeted synthetic basic anti-inflammatory drugs in elderly patients with rheumatoid arthritis: for or against;Problems of Geroscience;2024-06-30

5. Geschlechtersensible Aspekte in der Rheumatologie;Zeitschrift für Rheumatologie;2024-06-13